David Bakalov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Bakalov has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Anastassia Amaro
Penn Metabolic Medicine, Division of Endocrinology, University of Pennsylvania, Philadelphia, USA
1 shared publicationAndrew Chang
Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
1 shared publicationBijan Pesaran
Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
1 shared publication- Casey Harrison Halpern
University of Pennsylvania
1 shared publication Daniel Batista
Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, USA
1 shared publicationDisha Joshi
Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
1 shared publication
Latest Publications
- Open Access
- 17 November 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (12) , 4038-4043
Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide
Obesity and related conditions are associated with distressing food preoccupation that often culminates in dysregulated eating behaviors. Incretin-based therapies can reduce excessive weight in obesity, but their impact on dysregulated eating behaviors remains largely unexamined. Understanding how these pharmacologics engage the brain’s mesolimbic circuitry may inform the expansion of their therapeutic potential. We report a rare, first-in-human exploration of the physiological action of these therapies by examining the electrophysiology directly within the human nucleus accumbens. After a short-term course of tirzepatide, the patient-participant exhibited increased severe food preoccupation episodes, which were preceded by an increased delta–theta frequency (≤7 Hz) power in the nucleus accumbens region. We propose that the effects of an incretin-based therapy (tirzepatide) on food preoccupation may be associated with modulation of aberrant activity within this key hub of human mesolimbic circuitry.
- 17 November 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (12) , 4038-4043
Open AccessBrain activity associated with breakthrough food preoccupation in an individual on tirzepatide
Obesity and related conditions are associated with distressing food preoccupation that often culminates in dysregulated eating behaviors. Incretin-based therapies can reduce excessive weight in obesity, but their impact on dysregulated eating behaviors remains largely unexamined. Understanding how these pharmacologics engage the brain’s mesolimbic circuitry may inform the expansion of their therapeutic potential. We report a rare, first-in-human exploration of the physiological action of these therapies by examining the electrophysiology directly within the human nucleus accumbens. After a short-term course of tirzepatide, the patient-participant exhibited increased severe food preoccupation episodes, which were preceded by an increased delta–theta frequency (≤7 Hz) power in the nucleus accumbens region. We propose that the effects of an incretin-based therapy (tirzepatide) on food preoccupation may be associated with modulation of aberrant activity within this key hub of human mesolimbic circuitry.